Search
Cardio Diagnostics Holdings Inc
CDIOAdd to Watchlist
1.990USD
-0.120-5.69%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
5.89MMarket Cap
0.08P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-5.69%
5 Days
-1.00%
1 Month
-5.69%
6 Months
-29.93%
Year to Date
-26.57%
1 Year
-47.63%
Key Figures
2.120Open
2.125High
52.32KVolume
0.08P/E TTM
--P/E Dynamic
--Dividend TTM
1.77%Turnover Ratio
2.110Prev. Close
1.930Low
66.02KTurnover
LossP/E Static
0.66P/B
0.00%Div Yield TTM
-60.90%ROA
7.91052wk High
1.81Volume Ratio
-8.38MNet Profit
2.96MShares
24.7603EPS TTM
2.20Beta
-65.59%ROE
0.97052wk Low
9.24%Amplitude
100.00%Gross Margin
5.89MMarket Cap
--Reward/Risk
8.74%Risk Rate
TradingKey Stock Score of Cardio Diagnostics Holdings Inc
Currency: USD Updated: 2026-07-02Key Insights
Cardio Diagnostics Holdings Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 244 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 60.00.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Cardio Diagnostics Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Cardio Diagnostics Holdings Inc Highlights
StrengthsRisks
Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
Growing
The company is in a growing phase, with the latest annual income totaling USD 14.82K.
Overvalued
The company’s latest PE is 0.08, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 138.49K shares, decreasing 14.75% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 17.10K shares of this stock.
Analyst Rating
Based on
0
analysts
--
Current Rating
60.000
Target Price
+1227.43%
Upside Space
Cardio Diagnostics Holdings Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Cardio Diagnostics Holdings Inc Info
Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
Ticker SymbolCDIO
CompanyCardio Diagnostics Holdings Inc
CEODogan (Meeshanthini V)
Website
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Cardio Diagnostics Holdings Inc (CDIO)?
The current price of Cardio Diagnostics Holdings Inc (CDIO) is 1.99.
What is the symbol of Cardio Diagnostics Holdings Inc?
The ticker symbol of Cardio Diagnostics Holdings Inc is CDIO.
What is the 52-week high of Cardio Diagnostics Holdings Inc?
The 52-week high of Cardio Diagnostics Holdings Inc is 7.91.
What is the 52-week low of Cardio Diagnostics Holdings Inc?
The 52-week low of Cardio Diagnostics Holdings Inc is 0.97.
What is the market capitalization of Cardio Diagnostics Holdings Inc?
The market capitalization of Cardio Diagnostics Holdings Inc is 5.89M.
What is the Earnings Per Share (EPS TTM) of Cardio Diagnostics Holdings Inc (CDIO)?
The Earnings Per Share (EPS TTM) of Cardio Diagnostics Holdings Inc (CDIO) is -3.71.